Metabolic and Cardiovascular Disorders Development Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with metabolic diseases and at cardiovascular risk. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Internal Medicine Pipeline & Trials

Internal Medicine Pipeline as of April 28, 2020

  • Discovery Projects
  • Phase 1
    5
  • Phase 2
    4
  • Phase 3
    1
  • Registration
    1
  • Total11
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Chronic Pain due to Moderate-to-Severe Osteoarthritis (OA) (Biologic) (U.S., E.U.)
Project advanced
Registration New Molecular Entity Biologic
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Cancer Pain, Chronic Low Back Pain (Biologic) Phase 3 Product Enhancement Biologic
PF-05221304
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK) Phase 2 New Molecular Entity Small Molecule
PF-06835919
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Ketohexokinase (KHK) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) Phase 2 New Molecular Entity Small Molecule
PF-07055341
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
ACCi and DGAT2 Combination
Combo of PF-05221304 and PF-06865571 for Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 2 New Molecular Entity Small Molecule
vupanorsen (PF-07285557)
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Angiopoietin Like 3(ANGPTL3)
Cardiovascular Risk Reduction, Severe Hypertriglyceridemia Phase 2 New Molecular Entity Small Molecule
PF-06842874
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 4,6 Inhibitor
Pulmonary Arterial Hypertension Phase 1 New Molecular Entity Small Molecule
PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 1 New Molecular Entity Small Molecule
PF-06882961
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2, Obesity Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Factor Blocker
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
PF-07081532
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2, Obesity Phase 1 New Molecular Entity Small Molecule